When the symptoms are identical but the conditions aren't

Your knee is swollen, stiff, and aching after a run or a bad twist — and when you search your symptoms, two answers keep coming up: cartilage damage or arthritis. Both produce joint pain. Both cause swelling that worsens with activity. Both leave you struggling to fully straighten or bend the joint. If your GP has said 'it could be either at this stage', that is not a failure of diagnosis; it reflects a genuine clinical ambiguity that even experienced specialists take time to unpick.

Consider a 38-year-old who rolled their knee playing five-a-side four months ago. The joint swelled within hours, settled with rest, then flared again whenever they returned to sport. The MRI report mentions 'cartilage irregularity' and 'early degenerative change' — two phrases that sound similar but point in opposite directions. That is the crux of the problem.

The reason symptoms overlap so closely comes down to what cartilage actually is: a dense, glassy tissue that lines the ends of bones and contains neither blood vessels nor nerves. Pain signals from cartilage itself are indirect — they come from the surrounding structures that are irritated by the damage, which is why the ache is often diffuse and hard to pin down regardless of which condition is driving it.

But the two conditions are biologically different in a way that directly drives what can be done. A focal cartilage defect is a discrete injury — a hole or flap in a specific location — where the goal is structural repair and, in the right patient, regeneration. Osteoarthritis is a whole-joint degenerative process where the aim shifts to slowing decline and managing symptoms. Apply a repair procedure to established arthritis and it is likely to fail. Leave a repairable focal defect unaddressed and it can progress into arthritis that was never inevitable. Getting the distinction right is not a formality; it determines whether recovery is still on the table.

What focal cartilage damage actually looks like

Think of the cartilage surface inside a knee joint as a smooth, shock-absorbing lining. A focal chondral defect is a breach in that lining — a specific patch where the cartilage has thinned, cracked, or worn away entirely, rather than the surface degrading all over. A useful mental image is a pothole in an otherwise intact road: the damage is real and structurally significant, but the surrounding surface is still sound.

These lesions most commonly follow a clear mechanical event — a twisting injury during sport, a bad fall, or a previous knee problem — and are frequently found alongside damage to ligaments or the meniscus. The patient is often younger or physically active, and the onset is usually linked to a specific moment rather than a slow drift of worsening symptoms.

Clinicians grade focal lesions using the ICRS classification. Grade 1 is superficial softening without a visible break in the surface — significant enough to monitor, but structurally intact. Grade 2 extends less than halfway through the cartilage depth; Grade 3 goes deeper than half, with sub-grades progressing down to the bone beneath; Grade 4 breaks through the subchondral bone entirely. Surface area matters as much as depth: defects smaller than roughly 2–4 cm² are generally managed differently from those of 3 cm² or above, which tend to need more advanced reconstruction.

The critical clinical point is what surrounds the defect. In focal damage, the rest of the joint surface is often relatively preserved — the cartilage elsewhere has not yet begun to degenerate. That distinction is the biological foundation for repair: the joint environment is still healthy enough to support it.

What makes osteoarthritis different

Osteoarthritis tells a different story from the first paragraph. Rather than a discrete breach in an otherwise sound surface, it is a process that involves the whole joint — cartilage breakdown, remodelling of the bone beneath it, inflammation of the joint lining, and the formation of bony spurs around the joint margins. There is no single pothole to fill; the road itself is degrading.

The scale of the condition gives some sense of why this matters beyond any one patient: osteoarthritis is estimated to be the fourth leading cause of disability worldwide, affecting around 240 million people with symptoms significant enough to limit daily activity. That burden has shaped treatment philosophy — the clinical goal is management and preservation, not structural repair.

The joint environment is the clinical reason repair techniques do not transfer. Cartilage grafts and regenerative procedures depend on surrounding tissue that is biologically capable of supporting new growth. In an OA joint, that environment is compromised across the whole surface — placing a repair in degraded tissue is unlikely to hold. The management pathway therefore focuses on slowing progression, reducing inflammation, and protecting what remains: physiotherapy, load management, targeted injections, and bracing, with joint replacement reserved for end-stage disease.

Patients often recognise an OA pattern in their own history once they know what to look for. The onset tends to be gradual rather than event-linked, morning stiffness lasting more than half an hour is a common early sign, and symptoms may affect both knees or shift between joints over time — a broader, more diffuse picture than the mechanically triggered, location-specific discomfort that typically accompanies a focal chondral injury.

How the diagnosis is made — and where it can go wrong

Getting to a reliable diagnosis involves three overlapping steps: careful history-taking, imaging, and in some cases direct visualisation of the joint.

Clinical history comes first. Whether pain began after a specific event — a twist, a collision, a fall — or crept up without a clear trigger shifts the diagnostic probability before a single scan is ordered. Sudden onset with clicking, giving way, or locking points toward focal mechanical damage; gradual morning stiffness worsening over months sits more comfortably in a degenerative picture. That distinction, taken from the patient's own account, carries significant diagnostic weight before any imaging is reviewed.

MRI is the primary non-invasive tool, but it has a recognised limitation. Preoperative measurements of full-thickness defect area show an interrater reliability (ICC) of 0.74, and total abnormal cartilage area measurements reach 0.78 — both well short of the agreement a clinician would want when treatment choice is size-dependent. On a scale where 1.0 means perfect correspondence, these figures mean a lesion that reads as borderline on a scan may prove larger once a surgeon inspects it directly. Microfracture, mosaicplasty, and MACI are each indicated at different size thresholds, so that gap has real clinical consequences.

Arthroscopy remains the reference standard for definitive grading precisely for this reason. A lesion that appears moderate on MRI may be deeper or wider under direct inspection, and the ICRS grade assigned during arthroscopy is the figure that drives the final treatment plan.

Looking further ahead, 2025 research using Raman spectroscopy probes found molecular markers of cartilage softening and depleted glycosaminoglycans in tissue adjacent to focal lesions — areas that appeared entirely normal on conventional MRI and standard histopathology. The implication is that the boundary between a contained focal defect and very early diffuse degeneration may be less distinct than standard imaging suggests. It is one more reason why specialist-level assessment — not scan-reading alone — is what accurately classifies a lesion and determines whether repair remains a realistic option.

The grey zone — when focal damage and arthritis overlap

The two conditions described so far sit at opposite ends of a spectrum — but a significant number of patients land somewhere in the middle, and that grey zone is clinically real, not a diagnostic failure.

Focal chondral defects and osteoarthritis are not mutually exclusive categories. An untreated or mismanaged focal lesion can progress to diffuse joint degeneration over time, with the cartilage's structural inability to self-repair being the biological mechanism that drives that shift. The molecular evidence for this blurring was introduced above — early degenerative changes appearing at the margins of a focal lesion before macroscopic OA is visible — but the clinical implication extends further: by the time imaging shows unambiguous osteoarthritis, the window for structural cartilage repair may already have closed.

Not all focal defects follow that trajectory. Twelve-year follow-up data indicate meaningful individual variation in progression, and some lesions remain contained without developing into diffuse disease — a fact that is directly relevant to how prognosis is discussed. The difficulty is that no single validated biomarker yet exists to predict which path a given lesion will take. Research into combined diagnostic algorithms — pairing proteins such as IHh and IL-8 with patient demographics — suggests more reliable stratification may eventually be possible, but these tools remain in development rather than routine clinical use.

What this means in practice: patients who feel caught between two diagnoses may genuinely be in a biological grey zone. That ambiguity is not a reason to wait. It is a reason to seek precise specialist assessment early, while the full range of structural repair options still applies.

What the right diagnosis makes possible

A confirmed diagnosis does more than name the problem — it determines which treatment pathway is even appropriate to consider.

For a focal chondral defect in an otherwise healthy joint, the goal is structural repair. Small defects under roughly 2–4 cm² may be addressed with microfracture or osteochondral autograft transplantation (mosaicplasty). For larger defects of 3 cm² or more, the evidence increasingly favours cell-based repair: the SUMMIT trial demonstrated that Matrix-associated Autologous Chondrocyte Implantation (MACI) produced significantly better KOOS pain and function scores than microfracture at both two and five years. Standard microfracture generates fibrocartilage rather than true hyaline cartilage — a recognised limitation that affects long-term durability. High-density ACI (HD-ACI), which implants five million chondrocytes per cm², aims for hyaline-like repair tissue and is considered the strongest biological option for suitable focal lesions.

For appropriate candidates who are not ready for, or suited to, open surgery, less invasive options exist within the focal-defect pathway. ChondroFiller is a collagen-scaffold injectable designed for focal cartilage defects. NanoACi, developed by Professor Paul Lee, is a one-stage, needle-delivered technique that removes arthroscopy from the access pathway for suitable patients — an important distinction from traditional ACI, which requires two surgical stages. Neither option is suitable for a joint already affected by diffuse degeneration, which is why the diagnosis must be established first.

For confirmed osteoarthritis, repair surgery performs poorly. The surrounding tissue environment in a degenerative joint cannot support new cartilage growth, so treatment centres instead on physiotherapy, targeted injections, bracing, and — when conservative options are exhausted — joint replacement. Applying OA management to a focal defect delays, sometimes permanently, the structural repair that could have resolved the problem. Applying cartilage repair surgery to established OA wastes the intervention and can worsen outcomes.

That fork in the road is exactly why diagnosis has to come before treatment choice, not alongside it. A specialist assessment at MSK Doctors — consultant-led, no GP referral required, with open MRI available on-site in Sleaford — is the practical first step for anyone unsure which side of that fork they are standing on.

1. [1] Meniscus tear (knee cartilage damage) – NHS. https://www.nhs.uk/conditions/cartilage-damage/ https://www.nhs.uk/conditions/cartilage-damage/
2. [2] Hyaline Cartilage. https://en.wikipedia.org/?curid=1130627 https://en.wikipedia.org/?curid=1130627
3. [3] Articular Cartilage Damage. https://en.wikipedia.org/?curid=19057920 https://en.wikipedia.org/?curid=19057920
4. [4] Osteoarthritis. https://en.wikipedia.org/?curid=504841 https://en.wikipedia.org/?curid=504841
5. [5] Cartilage Defect Treatment Using High-Density Autologous Chondrocyte Implantation (HD-ACI). (2023). https://doi.org/10.3390/bioengineering10091083 https://doi.org/10.3390/bioengineering10091083
6. [6] Comparison of Knee Articular Cartilage Defect Size Between Measurements Obtained on Preoperative MRI Versus During Arthrotomy. (2023). https://doi.org/10.1177/23259671231193380 https://doi.org/10.1177/23259671231193380
7. [7] Raman Spectroscopic Probe Provides Optical Biomarkers of Cartilage Composition Predictive of Tissue Function. (2025). https://doi.org/10.1016/j.joca.2024.12.008 https://doi.org/10.1016/j.joca.2024.12.008
8. [8] MRI and Biomechanics Multidimensional Data Analysis Reveals R2-R1ρ as an Early Predictor of Cartilage Lesion Progression in Knee Osteoarthritis. (2017). https://doi.org/10.1002/jmri.25750 https://doi.org/10.1002/jmri.25750